XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2023
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Each Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   September 30,   December 31,   Accounting
Name of related party  2023   2022   treatments
Braingenesis Biotechnology Co., Ltd.   0.22%   0.22%  Cost Method
Genepharm Biotech Corporation   0.92%   0.92%  Cost Method
BioHopeKing Corporation   8.03%   8.03%  Cost Method
BioFirst Corporation   23.53%   21.77%  Equity Method
Rgene Corporation   28.85%   28.85%  Equity Method

 
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of related party   The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
Schedule of Long-Term Investment Long-term investment mainly consists of the following:
    September 30,
2023		     December 31,
2022		  
    (Unaudited)        
Non-marketable Cost Method Investments, net            
Braingenesis Biotechnology Co., Ltd.   $ 6,838     $ 7,169  
Genepharm Biotech Corporation     20,876       21,887  
BioHopeKing Corporation     775,491       813,014  
Sub total     803,205       842,070  
Equity Method Investments, net                
BioFirst Corporation    

1,874,190

       -  
Rgene Corporation     -       -  
Total   $

2,677,395

     $ 842,070  
Schedule of Balance Sheet Balance Sheet
   September 30,
2023		   December 31,
2022		 
   (Unaudited)     
Current Assets  $1,690,060   $1,543,152 
Non-current Assets   651,221    739,472 
Current Liabilities   2,236,708    2,663,051 
Non-current Liabilities   366,634    103,447 
Stockholders’ Equity (Deficit)   (262,061)   (483,874)

 

   September 30,
2023		   December 31,
2022		 
   (Unaudited)     
Current Assets  $56,091   $68,302 
Non-current Assets   239,594    303,893 
Current Liabilities   2,407,204    2,478,868 
Non-current Liabilities   1,465    2,441 
Shareholders’ Deficit   (2,112,984)   (2,109,114)
Schedule of Statement of Operation Statement of Operations
    Nine months Ended
September 30,		  
    2023     2022  
    (Unaudited)  
Net sales   $ 739     $ 23,079  
Gross profit     291       5,747  
Net loss     (986,181 )     (993,643 )
Share of losses from investments accounted for using the equity method     -       -   
   Nine months Ended
September 30,		 
   2023   2022 
   (Unaudited) 
Net sales  $-   $- 
Gross Profit   -    - 
Net loss   (231,445)   (450,995)
Share of loss from investments accounted for using the equity method   -    - 
Schedule of Components of Losses on Equity Investments The components of losses on equity investments for each period were as follows:
    Nine months Ended
September 30,		  
    2023     2022  
    (Unaudited)  
Share of equity method investee losses   $        -     $          -